6335-18-8

Basic information

• Product Name: 2-iodo-3,4-dimethoxybenzoic acid
• CAS NO: 6335-18-8
• Molecular Formula: C₉H₉IO₄
• Molecular Weight: 308.0698
• Mol File: 6335-18-8.mol

Chemical Properties

• Boiling Point: 370.2°C at 760 mmHg
• Flash Point: 177.7°C
• Density: 1.79g/cm³
• Vapor Pressure: 3.92E-06mmHg at 25°C
• Refractive Index: 1.607
• CAS DataBase Reference: 2-iodo-3,4-dimethoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-iodo-3,4-dimethoxybenzoic acid(6335-18-8)
• EPA Substance Registry System: 2-iodo-3,4-dimethoxybenzoic acid(6335-18-8)

Safety Data

• Hazardous Substances Data: 6335-18-8(Hazardous Substances Data)

Upstream product

• 621-59-0 isovanillin 
• 138490-94-5 2-iodoisovanillin 
• 93-07-2 Veratric acid 
• 138490-95-6 2-iodo-3,4-dimethoxybenzaldehyde 

Relevant articles and documents

Synthesis of 2,3,9,10-Tetraoxygenated benzo[c]phenanthridine derivatives via palladiummediated aryl-Aryl coupling reaction

Two 2,3,9,10-Tetraoxygenated benzo[c]phenanthridine alkaloids, 1 2, originally reported as zanthoxyline and broussonpapyrine, respectively, were synthesized using the Pd-mediated intramolecular aryl-Aryl coupling reaction as the key step.

Competition of substituents for ortho direction of metalation of veratric acid

LTMP (5 equiv) metalates randomly veratric acid (1). Under external quench conditions, the thermodynamically more stable lithium 2-lithio-3,4-dimethoxybenzoate (2) reacts with a variety of electrophiles to give versatile building units that are not easily accessible by conventional means. Under in situ quench conditions (LTMP/TMSCl), a reversal of regioselectivity is observed and 6-trimethylsilyl-3,4-dimethoxybenzoic acid (10) is formed predominantly.

Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.